Researchers at the Technion – Israel Institute of Technology have developed a nanomedicine approach that inhibits aggressive triple-negative breast cancer without delivering any drug, antibody or chemotherapy agent, according to the Technion's own announcement and a peer-reviewed paper in ACS Nano, corroborated by independent coverage from The Times of Israel and EurekAlert.
Rather than attacking cancer cells directly, the approach targets the tumor's surrounding environment. Macrophages, white blood cells whose normal role is to protect the body, are often "hijacked" by tumors, which use them to support their own growth and blunt the immune system's response. The Technion team's nanoparticles, called MPsomes, act as a biological decoy: they compete with immune cells for binding sites in the tumor microenvironment and block harmful cells' access to the tumor.
In cell cultures and in preclinical mouse models of triple-negative breast cancer — a form of the disease with limited treatment options — the particles accumulated in high concentrations around tumors and inhibited their growth with effectiveness the researchers describe as comparable to existing treatments. The Technion also reports a manufacturing process capable of producing about 20 milliliters of the nanoparticles per minute, roughly 1.2 liters per hour, a scale the university says supports further development toward clinical use.
The work has so far been demonstrated in cell cultures and animal models; it has not yet been tested in human clinical trials, and Lions of Zion is not aware of a published timeline for human studies.